Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Cancer Science

Volumn 102, Issue 12, 2011, Pages 2191-2198

  Chen, Szu Ta ^a   Jeng, Yung Ming ^a   Chang, Cheng Chi ^b   Chang, Hsiu Hao ^a   Huang, Min Chuan ^c   Juan, Hsueh Fen ^b   Hsu, Chun Hua ^b   Lee, Hsinyu ^b   Liao, Yung Feng ^d   Lee, Ya Ling ^c   Hsu, Wen Ming ^a   Lai, Hong Shiee ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; GELATINASE B; MATRIX METALLOPROTEINASE 14; MRNA BINDING PROTEIN 3; NEURON SPECIFIC ENOLASE; RETINOIC ACID; RNA BINDING PROTEIN; SOMATOMEDIN B; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NEUROBLASTOMA; ONCOGENE MYC; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA INTERFERENCE;

CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; PROGNOSIS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 81855222056     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02100.x     Document Type: Article

References (34)

1. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-20.
3. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20years after its "clinical debut". Eur J Cancer 2004; 40: 2639-42.
4. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169: 107-14.
5. Cohn SL, London WB, Huang D et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000; 18: 3604-13.
6. Tang XX, Zhao H, Kung B et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006; 66: 2826-33.
7. Mueller-Pillasch F, Pohl B, Wilda M et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999; 88: 95-9.
8. Hansen TV, Hammer NA, Nielsen J et al. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol 2004; 24: 4448-64.
9. Yantiss RK, Woda BA, Fanger GR et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005; 29: 188-95.
10. Yaniv K, Fainsod A, Kalcheim C, Yisraeli JK. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development 2003; 130: 5649-61.
11. Wagner M, Kunsch S, Duerschmied D et al. Transgenic overexpression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas. Gastroenterology 2003; 124: 1901-14.
12. Vikesaa J, Hansen TV, Jonson L et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006; 25: 1456-68.
13. Jiang Z, Chu PG, Woda BA et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7: 556-64.
14. Wang T, Fan L, Watanabe Y et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003; 88: 887-94.
15. Shimada H, Ambros IM, Dehner LP et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86: 349-63.
16. Shimada H, Ambros IM, Dehner LP et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86: 364-72.
17. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77.
18. Kopf I, Hanson C, Delle U et al. A rapid and simplified technique for analysis of archival formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization (FISH). Anticancer Res 1996; 16: 2533-6.
19. Tajiri T, Shono K, Fujii Y et al. Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization. J Pediatr Surg 1999; 34: 1615-9.
20. Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33: 1430-7.
21. Hsu WM, Jen YM, Lee H et al. The influence of biologic factors on the surgical decision in advanced neuroblastoma. Ann Surg Oncol 2006; 13: 238-44.
22. Jeng YM, Wang TH, Lu SH et al. Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg 2009; 96: 66-73.
23. Ikeda K, Tate G, Suzuki T et al. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol 2010; 41: 745-50.
24. Hsu WM, Lee H, Juan HF et al. Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis. Clin Cancer Res 2008; 14: 6237-45.
25. Ara T, Kusafuka T, Inoue M et al. Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression. J Pediatr Surg 2000; 35: 432-7.
26. Ribatti D, Surico G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 2001; 68: 1161-8.
27. Mahller YY, Vaikunth SS, Ripberger MC et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008; 68: 1170-9.
28. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
29. Cuende J, Moreno S, Bolaños JP, Almeida A. Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation. Oncogene 2008; 27: 3339-44.
30. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005; 280: 18517-24.
31. Yuan RH, Wang CC, Chou CC et al. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 2009; 16: 1711-9.
32. Liao B, Hu Y, Brewer G. RNA-binding protein IMP-3 promotes cell survival via IGF-II signaling after ionizing radiation. J Biol Chem 2011; 286: 31145-52.
33. Jeng YM, Chang CC, Hu FC et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 2008; 48: 1118-27.
34. Nielsen J, Christiansen J, Lykke-Andersen J et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999; 19: 1262-70.